::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

ALPHA – 1 ANTITRYPSIN AMONG NON-SMOKERS AND SMOKERS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

AUTHORS:

Dr Meryem Tanveer, Dr Farwa Sikandar, Dr Lubna Nawaz

ABSTRACT:

Aim: The aim of the present study is to correlate and compare alpha-1 antitrypsin level in smoker and nonsmoker chronic obstructive pulmonary disease patients. Place and Duration: Between May 2019 and May 2020, a study was conducted on COPD patients who went to the Department of Pulmonary Medicine at Nishtar Hospital Multan. Material and Methods: A comparative study was carried out in 200 subjects, more than 40 years of age and having chronic obstructive pulmonary disease for more than 1 year with a history of smoking at least 20 cigarettes per day (Group A) and without a history of smoking (Group B). Pulmonary function tests were used to diagnose the disease as per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification. Alpha-1 antitrypsin level was done by turbidimetry method on fully auto analyzer I-Lab 650 (Instrumentation Laboratory, USA) at Clinical Biochemistry Section. Statistical analysis was done by using unpaired t-test and Pearson’s correlation coefficient. Results: Results of present study shows that alpha-1 antitrypsin level was decreased in smoker chronic obstructive pulmonary disease patients (150.83±18.853) when compared to nonsmokers (183.97±29.383). There was statistically significant difference in alpha-1 antitrypsin level between the two groups with ‘p’ value of less than 0.0001. Pearson’s correlation test show negative correlation between smoker and non- smoker chronic obstructive pulmonary disease patients. Conclusion: The values of serum alpha-1 antitrypsin levels were more significantly decreased in smokers indicating an important role of smoking in pathogenesis of chronic obstructive pulmonary disease. Alpha-1 antitrypsin can act as a predictor for future development of chronic obstructive pulmonary disease in smokers and in nonsmokers. Keywords: Alpha-1 antitrypsin, Chronic Obstructive Pulmonary Disease (COPD), Forced Expiratory Volume (FEV), Global Initiative for Chronic Obstructive Lung Disease (GOLD)